Glaucoma
Conditions
Keywords
glaucoma, cornea, biomechanics
Brief summary
This pilot study evaluates the biomechanical properties of the cornea in glaucoma patients using Brillouin microscopy, a non-contact imaging technique. The study aims to compare corneal stiffness between patients with normal-tension glaucoma, high-tension glaucoma, and healthy controls, and to assess changes in corneal biomechanics following intraocular pressure (IOP)-lowering treatment. The goal is to determine whether Brillouin-derived biomechanical measurements can serve as biomarkers for glaucoma risk and progression.
Detailed description
This study explores the biomechanical properties of the cornea in patients with glaucoma using a novel, non-contact imaging technique called Brillouin microscopy. The technology allows in vivo assessment of tissue stiffness without physical perturbation, potentially offering new insights into glaucoma risk and response to therapy. The study includes two parts: a cross-sectional comparison between patients with normal- and high-tension glaucoma and healthy controls, and a longitudinal analysis of biomechanical changes following IOP-lowering treatment with either prostaglandin analogs or beta blockers. The goal is to determine whether corneal biomechanics can serve as a biomarker for glaucoma susceptibility and progression, and to evaluate the feasibility of integrating Brillouin imaging into clinical glaucoma care.
Interventions
Subjects with glaucoma may be prescribed prostaglandin analogs as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
DRUGBeta Blocker
Subjects with glaucoma may be prescribed topical beta blockers as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
DEVICEBrillouin Microscopy
Brillouin microscopy is a non-contact optical imaging method used to assess the biomechanical properties of the cornea in vivo with three-dimensional resolution. It will be used to evaluate corneal stiffness in all study subjects.
Sponsors
University of Maryland, Baltimore
National Eye Institute (NEI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
\- Age 18 years or older Diagnosis of primary open angle glaucoma (POAG) or no history of glaucoma (for controls) Open angle on gonioscopy (Shaffer grade 3 or 4) Best-corrected visual acuity of 20/25 or better Refractive error between +3.00 and -5.00 diopters No prior use of topical glaucoma medications Diagnosis of: High Tension Glaucoma (IOP ≥ 22 mmHg on 3 visits) Normal Tension Glaucoma (IOP ≤ 21 mmHg on 3 visits) OR age-matched control with normal optic nerve and visual fields
Exclusion criteria
Corneal abnormalities or conditions interfering with Brillouin or applanation tonometry Retinal diseases affecting RNFL (e.g., macular traction) History of ocular surgery or laser Diagnosis of diabetes History of uveitis History of prolonged steroid use Neurodegenerative or systemic diseases (e.g., multiple sclerosis, Alzheimer's, Parkinson's, schizophrenia) Unreliable visual fields Contraindications to beta blockers (e.g., bradycardia, severe pulmonary disease) Moderate to severe glaucoma (per Hodapp-Anderson-Parrish criteria) History of contact lens use Low blood pressure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Corneal Biomechanical Modulus | Baseline, 3 weeks, and 6 weeks | Brillouin microscopy will be used to measure the corneal modulus of elasticity. The primary outcome is the change in corneal stiffness (Brillouin shift in MHz) across time points in subjects treated with prostaglandin analogs versus beta blockers, and between groups at baseline (NTG, HTG, controls). |
Countries
United States
Contacts
CONTACTOsamah Saeedi, MD
PRINCIPAL_INVESTIGATOROsamah Saeedi, MD
University of Maryland, Baltimore
Outcome results
None listed